354 related articles for article (PubMed ID: 16214918)
1. Genetic polymorphisms of flavin monooxygenase 3 in sulindac-induced regression of colorectal adenomas in familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Schmotzer B; Easley KA; Hylind LM; Giardiello FM; Yang VW
Cancer Epidemiol Biomarkers Prev; 2005 Oct; 14(10):2366-9. PubMed ID: 16214918
[TBL] [Abstract][Full Text] [Related]
2. Genetic polymorphisms of human flavin monooxygenase 3 in sulindac-mediated primary chemoprevention of familial adenomatous polyposis.
Hisamuddin IM; Wehbi MA; Chao A; Wyre HW; Hylind LM; Giardiello FM; Yang VW
Clin Cancer Res; 2004 Dec; 10(24):8357-62. PubMed ID: 15623613
[TBL] [Abstract][Full Text] [Related]
3. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors.
Giardiello FM; Offerhaus JA; Tersmette AC; Hylind LM; Krush AJ; Brensinger JD; Booker SV; Hamilton SR
Gut; 1996 Apr; 38(4):578-81. PubMed ID: 8707091
[TBL] [Abstract][Full Text] [Related]
4. Combination of Sulindac and Bexarotene for Prevention of Intestinal Carcinogenesis in Familial Adenomatous Polyposis.
Bowen CM; Walter L; Borras E; Wu W; Ozcan Z; Chang K; Bommi PV; Taggart MW; Thirumurthi S; Lynch PM; Reyes-Uribe L; Scheet PA; Sinha KM; Vilar E
Cancer Prev Res (Phila); 2021 Sep; 14(9):851-862. PubMed ID: 34266857
[TBL] [Abstract][Full Text] [Related]
5. [Treatment with sulindac of adenomatous polyps in familial polyposis].
Cerdán FJ; Torres-Melero J; Martínez S; Gutiérrez del Olmo A; Balibrea JL
Rev Esp Enferm Dig; 1995 Aug; 87(8):574-6. PubMed ID: 7577106
[TBL] [Abstract][Full Text] [Related]
6. Effect of the non-steroidal anti-inflammatory drug sulindac on colorectal adenomas of uncolectomized familial adenomatous polyposis.
Matsumoto T; Nakamura S; Esaki M; Yao T; Iida M
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):251-7. PubMed ID: 16460482
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of human flavin-containing monooxygenase 3: implications for drug metabolism and clinical perspectives.
Hisamuddin IM; Yang VW
Pharmacogenomics; 2007 Jun; 8(6):635-43. PubMed ID: 17559352
[TBL] [Abstract][Full Text] [Related]
8. Effects of FMO3 Polymorphisms on Pharmacokinetics of Sulindac in Chinese Healthy Male Volunteers.
Tang YJ; Hu K; Huang WH; Wang CZ; Liu Z; Chen Y; Ouyang DS; Tan ZR; Zhou HH; Yuan CS
Biomed Res Int; 2017; 2017():4189678. PubMed ID: 28331852
[TBL] [Abstract][Full Text] [Related]
9. Rectal cancer after sulindac therapy for a sporadic adenomatous colonic polyp.
Matsuhashi N; Nakajima A; Shinohara K; Oka T; Yazaki Y
Am J Gastroenterol; 1998 Nov; 93(11):2261-6. PubMed ID: 9820411
[TBL] [Abstract][Full Text] [Related]
10. Effects of sulindac on sporadic colorectal adenomatous polyps.
Matsuhashi N; Nakajima A; Fukushima Y; Yazaki Y; Oka T
Gut; 1997 Mar; 40(3):344-9. PubMed ID: 9135523
[TBL] [Abstract][Full Text] [Related]
11. Sulindac for periampullary polyps in FAP patients.
Richard CS; Berk T; Bapat BV; Haber G; Cohen Z; Gallinger S
Int J Colorectal Dis; 1997; 12(1):14-8. PubMed ID: 9112144
[TBL] [Abstract][Full Text] [Related]
12. [Role of suindac in the treatment of familial adenomatous polyposis coli].
Landauer S; Halimi C; Caulin C; Bergmann JF
Therapie; 1999; 54(6):675-82. PubMed ID: 10709439
[TBL] [Abstract][Full Text] [Related]
13. Primary chemoprevention of familial adenomatous polyposis with sulindac.
Giardiello FM; Yang VW; Hylind LM; Krush AJ; Petersen GM; Trimbath JD; Piantadosi S; Garrett E; Geiman DE; Hubbard W; Offerhaus GJ; Hamilton SR
N Engl J Med; 2002 Apr; 346(14):1054-9. PubMed ID: 11932472
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of eflornithine (CPP-1X)/sulindac combination therapy versus each as monotherapy in patients with familial adenomatous polyposis (FAP): design and rationale of a randomized, double-blind, Phase III trial.
Burke CA; Dekker E; Samadder NJ; Stoffel E; Cohen A
BMC Gastroenterol; 2016 Aug; 16(1):87. PubMed ID: 27480131
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment with sulindac in familial adenomatous polyposis: is there an actual efficacy in prevention of rectal cancer?
Tonelli F; Valanzano R; Messerini L; Ficari F
J Surg Oncol; 2000 May; 74(1):15-20. PubMed ID: 10861602
[TBL] [Abstract][Full Text] [Related]
16. Sulindac in familial adenomatous polyposis: evaluation by nuclear morphometry.
Fernández-López F; Conde-Freire R; Cadarso-Suárez C; García-Iglesias J; Puente-Domínguez JL; Potel-Lesquereux J
Eur J Surg; 2001 May; 167(5):375-81. PubMed ID: 11419555
[TBL] [Abstract][Full Text] [Related]
17. Molecular analysis of sulindac-resistant adenomas in familial adenomatous polyposis.
Keller JJ; Offerhaus GJ; Drillenburg P; Caspers E; Musler A; Ristimäki A; Giardiello FM
Clin Cancer Res; 2001 Dec; 7(12):4000-7. PubMed ID: 11751493
[TBL] [Abstract][Full Text] [Related]
18. Relationship between APC genotype, polyp distribution, and oral sulindac treatment in the colon and rectum of patients with familial adenomatous polyposis.
Guldenschuh I; Hurlimann R; Muller A; Ammann R; Mullhaupt B; Dobbie Z; Zala GF; Flury R; Seelentag W; Roth J; Meyenberger C; Fried M; Hoppeler T; Spigelman AD; Scott RJ
Dis Colon Rectum; 2001 Aug; 44(8):1090-7; discussion 1097-9. PubMed ID: 11535846
[TBL] [Abstract][Full Text] [Related]
19. Flavin monooxygenase 3 (FMO3) polymorphism in a white population: allele frequencies, mutation linkage, and functional effects on clozapine and caffeine metabolism.
Sachse C; Ruschen S; Dettling M; Schley J; Bauer S; Müller-Oerlinghausen B; Roots I; Brockmöller J
Clin Pharmacol Ther; 1999 Oct; 66(4):431-8. PubMed ID: 10546928
[TBL] [Abstract][Full Text] [Related]
20. [The effects of sulindac on the pathology of colorectal remnant polyps of familial adenomatous polyposis (FAP) patients].
Li J; Lv YM; Jin Z; Cui RL
Beijing Da Xue Xue Bao Yi Xue Ban; 2005 Aug; 37(4):371-3. PubMed ID: 16086054
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
